I am still getting my head around it, but from what I gather...

I am still getting my head around it, but from what I gather Sphygmacor has been used and valuable in a clinical setting for many years, but expensive and not available for everyday use or feasible for most GPs, requires a clinician to operate. Sphygmacor is the tech that produces 16 BP measurements vs the existing BP monitors 3, I think the patents are pretty old but the complexity of replicating it is a moat anyhow and CDX have first mover advantage.

The Pulse device is Sphygmacor in a device similar in shape to the existing BP monitors for use at home, so same thing producing a more comprehensive result. BP monitors are a multi billion $ market, but I just don't see how the Pulse won't disrupt it when it appears vastly superior to what's currently for sale. And from what I understand first sales should be just a few months off now it's FDA approved. The Pulse being successful alone is many bags.

Then the Conneqt band, Sphygmacor in a watch, I feel this is still a way off and will require pretty complex engineering / design. I guess it's the holy grail though, disrupting that industry would be huge.